T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment.
T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories.
T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Friedrich-Bergius-Ring 15, Innovations- Und Gründerzentrum (Igz),germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://t-curx.com/
- HQ
- Würzburg, Bavaria
T-Curx Gmbh Questions
T-Curx Gmbh's website is https://t-curx.com/
T-Curx Gmbh's LinkedIn profile is https://de.linkedin.com/company/t-curx
T-Curx Gmbh has
11 employees.
View email and phone details for 11
employees at T-Curx Gmbh.
T-Curx Gmbh's industry is
Biotechnology Research
T-Curx Gmbh's top competitors are
Strüngmann Award,
Disco Pharmaceuticals Gmbh,
Boehringer Ingelheim,
Vsquared Ventures,
Haya Therapeutics,
Pentixapharm Ag,
Nbe-Therapeutics Ag,
Heparegenix Gmbh,
Tigen,
Tubulis Gmbh.
T-Curx Gmbh's categories are Biotechnology Research
T-Curx Gmbh's founding year is 2017
